X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
diagnosed chronic-phase (166) 166
humans (160) 160
index medicus (160) 160
follow-up (118) 118
hematology (110) 110
chronic myelogenous leukemia (109) 109
chronic myeloid leukemia (109) 109
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (109) 109
oncology (99) 99
imatinib (85) 85
imatinib mesylate (78) 78
dasatinib (77) 77
nilotinib (74) 74
protein kinase inhibitors - therapeutic use (72) 72
tyrosine kinase inhibitors (68) 68
female (66) 66
male (62) 62
antineoplastic agents - therapeutic use (60) 60
pyrimidines - therapeutic use (59) 59
middle aged (58) 58
aged (54) 54
adult (53) 53
chronic myeloid-leukemia (53) 53
treatment outcome (53) 53
piperazines - therapeutic use (48) 48
leukemia (45) 45
protein-tyrosine kinases - antagonists & inhibitors (39) 39
leukemia, myelogenous, chronic, bcr-abl positive - genetics (35) 35
bcr-abl (33) 33
aged, 80 and over (32) 32
benzamides - therapeutic use (32) 32
young adult (32) 32
care and treatment (31) 31
pyrimidines - administration & dosage (31) 31
tyrosine (31) 31
patients receiving imatinib (30) 30
prognosis (30) 30
pyrimidines - adverse effects (30) 30
hemic and lymphatic diseases (29) 29
interferon-alpha (29) 29
tyrosine kinase inhibitor (29) 29
fusion proteins, bcr-abl - genetics (28) 28
molecular response (28) 28
cml (26) 26
protein kinase inhibitors - adverse effects (26) 26
therapy (26) 26
medicine & public health (25) 25
protein kinase inhibitors - administration & dosage (24) 24
benzamides (23) 23
cancer (23) 23
drug therapy (23) 23
hematology, oncology and palliative medicine (23) 23
leukemia, myeloid, chronic-phase - drug therapy (23) 23
piperazines - adverse effects (23) 23
trial (23) 23
piperazines - administration & dosage (22) 22
adolescent (21) 21
antineoplastic agents - administration & dosage (21) 21
complete molecular remission (21) 21
follow-up studies (21) 21
research (21) 21
thiazoles - therapeutic use (20) 20
antineoplastic agents - adverse effects (19) 19
clinical trials (19) 19
fusion proteins, bcr-abl - antagonists & inhibitors (19) 19
antineoplastic agents (18) 18
drug resistance, neoplasm (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - mortality (18) 18
mutation (18) 18
philadelphia-chromosome (18) 18
analysis (17) 17
antimitotic agents (17) 17
bcr-abl1 (17) 17
benzamides - administration & dosage (17) 17
retrospective studies (17) 17
cml patients (16) 16
disease-free survival (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - pathology (16) 16
pharmacology & pharmacy (16) 16
protein-tyrosine kinase (16) 16
benzamides - adverse effects (15) 15
complete cytogenetic response (15) 15
fusion proteins, bcr-abl - metabolism (15) 15
abridged index medicus (14) 14
discontinuation (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - therapy (14) 14
medicine, general & internal (14) 14
minimal residual disease (14) 14
myeloid leukemia (14) 14
newly-diagnosed patients (14) 14
patients (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
bcr-abl mutations (13) 13
health aspects (13) 13
time factors (13) 13
tyrosine kinase (13) 13
acute lymphoblastic-leukemia (12) 12
alpha plus cytarabine (12) 12
article (12) 12
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
AMERICAN JOURNAL OF HEMATOLOGY, ISSN 0361-8609, 07/2014, Volume 89, Issue 7, pp. 732 - 742
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2015, Volume 90, Issue 1, pp. 37 - 41
Journal Article
CANCER, ISSN 0008-543X, 12/2013, Volume 119, Issue 24, pp. 4284 - 4289
BACKGROUND: The pegylated form of interferon--2a (PegIFNa2a) in combination with imatinib has demonstrated a molecular improvement in patients with... 
clinical trial | CHRONIC MYELOGENOUS LEUKEMIA | STEM-CELLS | imatinib | molecular response | FOLLOW-UP | DASATINIB | interferon | NILOTINIB | TRIAL | ONCOLOGY | DIAGNOSED CHRONIC-PHASE | chronic myeloid leukemia | QUIESCENT | IFN-ALPHA | Drugs | Interferon alfa-2a | Evaluation | Usage | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Health aspects
Journal Article
BLOOD, ISSN 0006-4971, 11/2008, Volume 112, Issue 10, pp. 3965 - 3973
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2013, Volume 13, Issue 5, pp. 584 - 591
Journal Article
Journal Article